|
1
|
Rothermundt C, Seddon BM, Dileo P, Strauss
SJ, Coleman J, Briggs TW, Haile SR and Whelan JS: Follow-up
practices for high-grade extremity Osteosarcoma. BMC Cancer.
16:3012016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kager L, Zoubek A, Pötschger U, Kastner U,
Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M,
Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation
and outcome of patients treated on neoadjuvant cooperative
osteosarcoma study group protocols. J Clin Oncol. 21:2011–2018.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Senerchia AA, Macedo CR, Ferman S,
Scopinaro M, Cacciavillano W, Boldrini E, Lins de Moraes VL, Rey G,
de Oliveira CT, Castillo L, et al: Results of a randomized,
prospective clinical trial evaluating metronomic chemotherapy in
nonmetastatic patients with high-grade, operable osteosarcomas of
the extremities: A report from the Latin American Group of
Osteosarcoma Treatment. Cancer. 123:1003–1010. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chung SW, Han I, Oh JH, Shin SH, Cho HS
and Kim HS: Prognostic effect of erroneous surgical procedures in
patients with osteosarcoma: Evaluation using propensity score
matching. J Bone Joint Surg Am. 96:e602014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng C, Chen ZQ and Shi XT: MicroRNA-320
inhibits osteosarcoma cells proliferation by directly targeting
fatty acid synthase. Tumour Biol. 35:4177–4183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li E, Zhang J, Yuan T and Ma B: MiR-145
inhibits osteosarcoma cells proliferation and invasion by targeting
ROCK1. Tumour Biol. 35:7645–7650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rinn JL and Chang HY: Genome regulation by
long noncoding RNAs. Annu Rev Biochem. 81:145–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ponjavic J, Ponting CP and Lunter G:
Functionality or transcriptional noise? Evidence for selection
within long noncoding RNAs. Genome Res. 17:556–565. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
ENCODE Project Consortium, ; Birney E,
Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH,
Weng Z, Snyder M, Dermitzakis ET, et al: Identification and
analysis of functional elements in 1% of the human genome by the
ENCODE pilot project. Nature. 447:799–816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hirano T, Yoshikawa R, Harada H, Harada Y,
Ishida A and Yamazaki T: Long noncoding RNA, CCDC26, controls
myeloid leukemia cell growth through regulation of KIT expression.
Mol Cancer. 14:902015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen F, Mo J and Zhang L: Long noncoding
RNA BCAR4 promotes osteosarcoma progression through activating
GLI2-dependent gene transcription. Tumour Biol. 37:13403–13412.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Raveh E, Matouk IJ, Gilon M and Hochberg
A: The H19 Long non-coding RNA in cancer initiation, progression
and metastasis-a proposed unifying theory. Mol Cancer. 14:1842015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Modali SD, Parekh VI, Kebebew E and
Agarwal SK: Epigenetic regulation of the lncRNA MEG3 and its target
c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol.
29:224–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu XS, Wang F, Li HF, Hu YP, Jiang L,
Zhang F, Li ML, Wang XA, Jin YP, Zhang YJ, et al: LncRNA-PAGBC acts
as a microRNA sponge and promotes gallbladder tumorigenesis. EMBO
Rep. 18:1837–1853. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao J, Lv Y, Jin F, Liu Y, Ma Y, Xiong Y,
Liu L, Zhang S, Sun Y, Tipoe GL, et al: LncRNA HANR promotes
tumorigenesis and increase of chemoresistance in hepatocellular
carcinoma. Cell Physiol Biochem. 43:1926–1938. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu X, Feng Y, Zhang D, Zhao SD, Hu Z,
Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, et al: A functional
genomic approach identifies FAL1 as an oncogenic long noncoding RNA
that associates with BMI1 and represses p21 expression in cancer.
Cancer Cell. 26:344–357. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peng W, Si S, Zhang Q, Li C, Zhao F, Wang
F, Yu J and Ma R: Long non-coding RNA MEG3 functions as a competing
endogenous RNA to regulate gastric cancer progression. J Exp Clin
Cancer Res. 34:792015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun L, Yang C, Xu J, Feng Y, Wang L and
Cui T: Long noncoding RNA EWSAT1 promotes osteosarcoma cell growth
and metastasis through suppression of MEG3 expression. DNA Cell
Biol. 35:812–818. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Z, Yu X and Shen J: Long non-coding
RNAs: Emerging players in osteosarcoma. Tumour Biol. 37:2811–2816.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cui X, Jing X, Long C, Tian J and Zhu J:
Long noncoding RNA MEG3, a potential novel biomarker to predict the
clinical outcome of cancer patients: A meta-analysis. Oncotarget.
8:19049–19056. 2017.PubMed/NCBI
|
|
23
|
Ying L, Huang Y, Chen H, Wang Y, Xia L,
Chen Y, Liu Y and Qiu F: Downregulated MEG3 activates autophagy and
increases cell proliferation in bladder cancer. Mol Biosyst.
9:407–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin R, Chen Z, Ding Y, Hao J, Hu J and Guo
F: Long noncoding RNA MEG3 inhibits the proliferation of cervical
carcinoma cells through the induction of cell cycle arrest and
apoptosis. Neoplasma. 60:486–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang L, Wang G, Jia T, Zhang L, Li Y, Han
Y, Zhang K, Lin G, Zhang R, Li J and Wang L: Armored long
non-coding RNA MEG3 targeting EGFR based on recombinant MS2
bacteriophage virus-like particles against hepatocellular
carcinoma. Oncotarget. 7:23988–24004. 2016.PubMed/NCBI
|
|
26
|
Cao X, Zhuang S, Hu Y, Xi L, Deng L, Sheng
H and Shen W: Associations between polymorphisms of long noncoding
RNA MEG3 and risk of colorectal cancer in Chinese. Oncotarget.
7:19054–19059. 2016.PubMed/NCBI
|
|
27
|
Zhu F, Zhang X, Yu Q, Han G, Diao F, Wu C
and Zhang Y: LncRNA AWPPH inhibits SMAD4 via EZH2 to regulate
bladder cancer progression. J Cell Biochem. 119:4496–4505. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu G, Wang W, Deng J and Dong S: LncRNA
AWPPH promotes the proliferation, migration and invasion of ovarian
carcinoma cells via activation of the Wnt/β-catenin signaling
pathway. Mol Med Rep. 19:3615–3621. 2019.PubMed/NCBI
|
|
29
|
Zhao X, Liu Y and Yu S: Long noncoding RNA
AWPPH promotes hepatocellular carcinoma progression through YBX1
and serves as a prognostic biomarker. Biochim Biophys Acta Mol
Basis Dis. 1863:1805–1816. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo D, Li Q, Lv Q, Wei Q, Cao S and Gu J:
MiR-27a targets sFRP1 in hFOB cells to regulate proliferation,
apoptosis and differentiation. PLoS One. 9:e913542014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bielack S, Carrle D and Casali PG; ESMO
Guidelines Working Group, : Osteosarcoma: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
20 (Suppl 4):S137–S139. 2009. View Article : Google Scholar
|
|
33
|
Zhang J, Lan Q and Lin J: Identification
of key gene modules for human osteosarcoma by co-expression
analysis. World J Surg Oncol. 16:892018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bassett AR, Akhtar A, Barlow DP, Bird AP,
Brockdorff N, Duboule D, Ephrussi A, Ferguson-Smith AC, Gingeras
TR, Haerty W, et al: Considerations when investigating lncRNA
function in vivo. Elife. 3:e030582014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Danielsen SA, Eide PW, Nesbakken A, Guren
T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in
colorectal cancer. Biochim Biophys Acta. 1855:104–121.
2015.PubMed/NCBI
|
|
37
|
Gardai SJ, Hildeman DA, Frankel SK,
Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL and
Henson PM: Phosphorylation of Bax Ser184 by Akt regulates its
activity and apoptosis in neutrophils. J Biol Chem.
279:21085–21095. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Quan JH, Cha GH, Zhou W, Chu JQ, Nishikawa
Y and Lee YH: Involvement of PI 3 kinase/Akt-dependent Bad
phosphorylation in Toxoplasma gondii-mediated inhibition of host
cell apoptosis. Exp Parasitol. 133:462–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cardone MH, Roy N, Stennicke HR, Salvesen
GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of
cell death protease caspase-9 by phosphorylation. Science.
282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li C, Yu S, Wu S, Ni Y and Pan Z:
MicroRNA-936 targets FGF2 to inhibit epithelial ovarian cancer
aggressiveness by deactivating the PI3K/Akt pathway. Onco Targets
Ther. 12:5311–5322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee MS, Jeong MH, Lee HW, Han HJ, Ko A,
Hewitt SM, Kim JH, Chun KH, Chung JY, Lee C, et al: PI3K/AKT
activation induces PTEN ubiquitination and destabilization
accelerating tumourigenesis. Nat Commun. 6:77692015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hu B, Lv X, Gao F, Chen S, Wang S, Qing X,
Liu J, Wang B and Shao Z: Downregulation of DEPTOR inhibits the
proliferation, migration, and survival of osteosarcoma through
PI3K/Akt/mTOR pathway. Onco Targets Ther. 10:4379–4391. 2017.
View Article : Google Scholar : PubMed/NCBI
|
